Modulation of T-Cell Costimulation as Immunotherapy or Immunochemotherapy in Experimental Visceral Leishmaniasis

Infection and Immunity

Volumn 71, Issue 11, 2003, Pages 6453-6462

  Murray, Henry W ^a   Lu, Cristina M ^a   Brooks, Elaine B ^a   Fichtl, Richard E ^b   DeVecchio, Jennifer L ^c   Heinzel, Frederick P ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; CD40 ANTIGEN; CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 12; MONOCLONAL ANTIBODY; STIBOGLUCONATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL KILLING; CELL MIGRATION; CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG TARGETING; FEMALE; GRANULOMA; IMMUNOCHEMOTHERAPY; IMMUNOTHERAPY; INFECTION RESISTANCE; LEISHMANIA DONOVANI; MACROPHAGE; MACROPHAGE ACTIVATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, DIFFERENTIATION; CD40 LIGAND; FEMALE; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEIN SUBUNITS; T-LYMPHOCYTES;

EID: 0242286545     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.11.6453-6462.2003     Document Type: Article

References (43)

1. Alexander, J., K. C. Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher. 2000. Endogenous-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30:2935-2943.
2. Balkhy, H. H., and F. P. Heinzel. 1999. Endotoxin fails to induce interferon-γ in endotoxin tolerant mice: deficiencies in both IL-12 heterodimer production and IL-12 responsiveness. J. Immunol. 162:3633-3638.
3. Belkaid, Y. S., S. Mendez, R. Lira, N. Kadambi, G. Milon, and D. Sacks. 2000. A natural model of Leishmania major infection reveals a profound "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. 165:969-976.
4. Campbell, K. A., P. J. Ovendale, M. K. Kennedy, W. C. Fanslow, S. G. Reed, and C. R. Maliszewski. 1996. CD40 ligand is required for protective cellmediated immunity to Leishmania major. Immunity 4:283-289.
5. Cella, M., D. Scheidegger, L. K. Palmer, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747-752.
6. Engwerda, C. R., M. L. Murphy, S. E. Cotterell, S. C. Smelt, and P. M. Kaye. 1998. Neutralization of IL-12 demonstrates the existence of discrete organspecific phases in the control of Leishmania donovani. Eur. J. Immunol. 28:669-680.
7. Ferlin, W. G., T. von der Weid, F. Cottrez, D. A. Ferrick, R. L. Coffman, and M. C. Howard. 1998. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb. Eur. J. Immunol. 28:525-531.
8. Frauwirth, K. A., and C. B. Thompson. 2002. Activation and inhibition of lymphocytes by costimulation. J. Clin. Investig. 109:295-299.
9. French, R. R., H. T. C. Chan, A. L. Tutt, and M. J. Glennie. 1999. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5:548-553.
10. Gomes, N. A. 2001. The dual role of CTLA-4 in Leishmania infection. Trends Parasitol. 17:487-491.
11. Gomes, N. A., V. Barretto-de-Souza, M. E. Wilson, and G. A. DosReis. 1998. Unresponsive CD4+ T lymphocytes from Leishmania chagasi-infected mice increase cytokine production and mediate parasite killing after blockade of B7-1/CTLA-4 molecular pathway. J. Infect. Dis. 178:1847-1851.
12. Greenwald, R. J., A. J. McAdam, D. Van der Woude, A. B. Saroskar, and A. H. Sharpe. 2002. Cutting edge: inducible costimulator protein regulates both Th1 and Th2 responses to cutaneous leishmaniasis. J. Immunol. 168:991-995.
13. Grewal, I. S., and R. A. Flavell. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:111-135.
14. Heinzel, F. P., R. M. Rerko, and A. M. Hujer. 1998. Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity. Cell. Immunol. 184:129-142.
15. Heinzel, F. P., and R. A. Maier. 1999. Interleukin-4-independent acceleration of cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-CTLA-4 antibody. Infect. Immun. 67:6454-6460.
16. Hixon, J. A., B. R. Blazar, M. R. Anver, R. H. Wiltrout, and W. J. Murphy. 2001. Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. Biol. Blood Marrow Transplant. 7:136-143.
17. Kamanaka, M., P. Yu, T. Yasui, K. Yoshide, T. Kawabe, T. Horii, T. Kishimoto, and H. Kikutanti. 1996. Protective role of CD40 in Leishmania major infection at distinct phases of cell-mediated immunity. Immunity 4:275-281.
18. Martin, D. L., C. L. King, E. Pearlman, E. Strine, and F. P. Heinzel. 2000. IFN-γ is necessary but not sufficient for anti-CD40 antibody-mediated inhibition of the Th2 response to Schistosoma mansoni eggs. J. Immunol. 64:779-785.
19. Murphy, M. L., C. R. Engwerda, P. M. A. Gorak, and P. M. Kaye. 1997. B7-2 blockade enhances T cell responses to Leishmania donovani. J. Immunol. 159:4460-4466.
20. Murphy, M. L., S. Cotterell, M. Gorak, C. R. Engwerda, and P. M. Kaye. 1998. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J. Immunol. 161:4153-4160.
21. Murray, H. W. 1990. Effect of continuous administration of interferongamma in experimental visceral leishmaniasis. J. Infect. Dis. 161:992-994.
22. Murray, H. W. 2000. Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation, Infect. Immun. 68:6294-6299.
23. Murray, H. W. 2001. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 45:2185-2197.
24. Murray, H. W. 2001. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int. J. Exp. Pathol. 82:249-267.
25. Murray, H. W., J. D. Berman, and S. D. Wright. 1988. Immunochemotherapy for intracellular Leishmania donovani infection: interferon-gamma plus pentavalent antimony. J. Infect. Dis. 157:973-978.
26. Murray, H. W., and C. F. Nathan. 1999. Macrophage microbicidal mechanisms in vivo: reactive nitrogen vs. oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189:741-746.
27. Murray, H. W., and S. Delph-Etienne. 2000. Role of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68:288-293.
28. Murray, H. W., C. Montelibano, R. Peterson, and J. P. Sypek. 2000. Interleukin 12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 182:1497-1502.
29. Murray, H. W., A. Jungbluth, E. Ritter, C. Montelibano, and M. W. Marino. 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68:6289-6293.
30. Murray, H. W., C. M. Lu, S. Mauze, S. Freeman, A. L. Moreira, G. Kapla, and R. L. Coffman. 2002. Interleukin 10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70:6284-6293.
31. Murray, H. W., A. L. Moreira, C. M. Lu, J. L. DeVecchio, M. Matsuhashi, X. Ma, and F. P. Heinzel. Determinants of response to interleukin 10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 188:458-464.
32. Padigel, U. M., P. J. Perrin, and J. P. Farrell. 2001. The development of a Th1-type response and resistance to Leishmania major infection in the absence of CD40-CD40L costimulation. J. Immunol. 167:5874-5879.
33. Qi, H., V. Popov, and L. Soong. 2001. Leishmania amazonensis-dendritic cell interactions in vitro and the priming of parasite-specific CD4+ T cells in vivo. J. Immunol. 167:4534-4542.
34. Satoskar, A. R., S. Rodig, S. R. Telford, A. A. Satoskar, S. K. Ghosh, F. von Lichtenberg, and J. R. David. 2000. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic pathology. Eur. J. Immunol. 30:834-839.
35. Schultze, J., and P. Johnson. 1999. A stimulating new target for cancer immunotherapy. Lancet 354:1225-1226.
36. Shiloh, M. U., J. D. MacMicking, S. Nicholson, J. E. Brause, S. Potter, M. Marino, F. Fang, M. Dinauer, and C. Nathan. 1999. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 10:29-38.
37. Soong, L., J.-C. Xu, I. S. Grewal, P. Kima, J. Sun, B. J. Longley, N. H. Ruddle, D. McMahon-Pratt, and R. A. Flavell. 1996. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4:263-273.
38. Speirs, K., J. Caamano, M. H. Golschmidt, C. A. Hunter, and P. Scott. 2002. NF-κB2 is required for optimal CD40-induced IL-12 production but dispensable for Th1 cell differentiation J. Immunol. 168:4406-4413.
39. Stout, R. D., and J. Suttles. 1996. The many roles of CD40 in cell-mediated inflammatory responses. Immunol. Today 17:487-492.
40. Taylor, A., and H. W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-γ: effect of interleukin 12 in experimental visceral leishmaniasis in interferon-γ gene-disrupted mice. J. Exp. Med. 185:1231-1239.
41. Thompson, C. B., and J. P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity 7:445-450.
42. Tian, L., R. J. Noelle, and D. A. Lawrence. 1995. Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur. J. Immunol. 25:306-309.
43. Watts, T. H., and M. A. DeBenedette. 1999. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11:286-293.